Alzheimer's disease is the most common type of dementia and ... In this sense, Malagelada points out that "if we can design ...

An elderly patient died in a clinical study of Roche Holding AG’s experimental treatment for Alzheimer’s disease, prompting ...

Second-year computer science (CS) majors and entrepreneurs Syed Husain and Vihaan Nagarkar developed MemoLens as participants ...

Personalized repetitive transcranial magnetic stimulation slowed cognitive and functional impairment in a phase 2 study of ...

Alzheimer's Disease (AD) is a growing global public health ... Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management ...

Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Al ...

As the world of neurodegenerative disease drug development continues to be roiled by controversies, one company has taken a ...

CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...

The only approved treatments for Alzheimer’s disease are medications with limited effectiveness and a risk of severe, sometimes deadly, side effects. That’s why scientists search for therapies ...

Training for the proprietary program is aimed at implementing the latest evidenced-based approaches to dementia care amid the ...

The trial’s design, which includes comprehensive biomarker analysis, aims to assess the impact on the amyloid signaling pathway and neuroinflammation, reinforcing Alector’s innovative approach in the ...

Alzheimer's disease is the most common type ... In this sense, Malagelada points out that "if we can design inhibitors of the RTP801 protein—which we are currently working on—or preserve ...